Article
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2015
Geater Sarayut L, Xu Chong-Rui, Zhou Caicun, Hu Cheng-Ping, Feng Jifeng, Lu Shun, Huang Yunchao, Li Wei, Hou Mei, Shi Jian Hua, Lee Kye Young, Palmer Michael, Shi Yang, Lungershausen Juliane, Wu Yi-Long
Abstract excerpt
INTRODUCTION: In the phase III, LUX-Lung 6 trial, afatinib prolonged progression-free survival (PFS) versus cisplatin/gemcitabine in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). This article provides detailed assessments of pati...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.